The HER2CLIMB-05 trial is a randomized, double blind, placebo-controlled, pivotal Phase 3 study evaluating the efficacy and safety of TUKYSA compared to placebo, both in combination with trastuzumab ...
NEW YORK-- (BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, ...
LITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a ...
(NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-t ...
Data across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig ...
2026-2027 COVID-19 vaccine formula targets the XFG variant, in line with FDA guidance to more closely match contemporary circulating variants Shipping will begin immediately to ensure rapid access to ...
Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
Two pivotal studies of LITFULO™ (ritlecitinib) in nonsegmental vitiligo met their co-primary endpoints, showing significant improvement in facial and total repigmentation versus placebo at Week 52 ...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a ...
Primary endpoint met at the interim analysis in MagnetisMM-5 trial demonstrating a statistically significant and clinically meaningful improvement in progression-free survival Safety was consistent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results